Chris Schott
Stock Analyst at JP Morgan
(3.84)
# 534
Out of 5,182 analysts
156
Total ratings
59.26%
Success rate
6.54%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Overweight | $125 → $135 | $111.90 | +20.64% | 8 | Apr 6, 2026 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $225 → $250 | $227.50 | +9.89% | 1 | Mar 5, 2026 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $24 → $28 | $22.75 | +23.08% | 5 | Feb 19, 2026 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,150 → $1,300 | $883.96 | +47.07% | 24 | Feb 5, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $850 → $950 | $751.57 | +26.40% | 9 | Feb 2, 2026 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Overweight | $28 → $35 | $30.64 | +14.23% | 20 | Dec 16, 2025 | |
| PRGO Perrigo Company | Maintains: Neutral | $20 → $18 | $11.82 | +52.28% | 14 | Dec 15, 2025 | |
| OGN Organon & Co. | Maintains: Underweight | $14 → $12 | $11.26 | +6.57% | 3 | Nov 11, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $230 → $200 | $116.87 | +71.13% | 3 | Nov 5, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $675 → $775 | $565.93 | +36.94% | 9 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $260 | $198.71 | +30.84% | 4 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $145 → $150 | $130.40 | +15.03% | 8 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $12.52 | +11.82% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $185 → $175 | $184.38 | -5.09% | 4 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $49.38 | -14.95% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $344.55 | -21.64% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $27.00 | +25.93% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $14.59 | -4.04% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $1.75 | +528.57% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.63 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $58.71 | +32.86% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $0.14 | +697,916.16% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.19 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $24.51 | +104.00% | 3 | Nov 2, 2018 |
Merck & Co.
Apr 6, 2026
Maintains: Overweight
Price Target: $125 → $135
Current: $111.90
Upside: +20.64%
Johnson & Johnson
Mar 5, 2026
Maintains: Neutral
Price Target: $225 → $250
Current: $227.50
Upside: +9.89%
Elanco Animal Health
Feb 19, 2026
Maintains: Overweight
Price Target: $24 → $28
Current: $22.75
Upside: +23.08%
Eli Lilly and Company
Feb 5, 2026
Maintains: Overweight
Price Target: $1,150 → $1,300
Current: $883.96
Upside: +47.07%
Regeneron Pharmaceuticals
Feb 2, 2026
Maintains: Overweight
Price Target: $850 → $950
Current: $751.57
Upside: +26.40%
Teva Pharmaceutical Industries
Dec 16, 2025
Maintains: Overweight
Price Target: $28 → $35
Current: $30.64
Upside: +14.23%
Perrigo Company
Dec 15, 2025
Maintains: Neutral
Price Target: $20 → $18
Current: $11.82
Upside: +52.28%
Organon & Co.
Nov 11, 2025
Maintains: Underweight
Price Target: $14 → $12
Current: $11.26
Upside: +6.57%
Zoetis
Nov 5, 2025
Maintains: Overweight
Price Target: $230 → $200
Current: $116.87
Upside: +71.13%
IDEXX Laboratories
Nov 4, 2025
Maintains: Overweight
Price Target: $675 → $775
Current: $565.93
Upside: +36.94%
Nov 3, 2025
Maintains: Overweight
Price Target: $250 → $260
Current: $198.71
Upside: +30.84%
Oct 31, 2025
Maintains: Overweight
Price Target: $145 → $150
Current: $130.40
Upside: +15.03%
Sep 16, 2025
Maintains: Overweight
Price Target: $12 → $14
Current: $12.52
Upside: +11.82%
May 5, 2025
Maintains: Neutral
Price Target: $185 → $175
Current: $184.38
Upside: -5.09%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $49.38
Upside: -14.95%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $344.55
Upside: -21.64%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $27.00
Upside: +25.93%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $14.59
Upside: -4.04%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $1.75
Upside: +528.57%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $5.63
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $58.71
Upside: +32.86%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $0.14
Upside: +697,916.16%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $2.19
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $24.51
Upside: +104.00%